Show simple item record

AuthorGiannopoulos, Krzysztofdc.contributor.author
Date of accession2016-03-14T13:40:07Zdc.date.accessioned
Available in OPARU since2016-03-14T13:40:07Zdc.date.available
Year of creation2005dc.date.created
AbstractSpecific immunotherapy might be a novel option for therapy of patients with B-cell chronic lymphocytic leukemia (B-CLL).To define potential target antigens, we screened the mRNA expression of twelve tumor/leukemia associated antigens (TAA/LAAs) from the literature: fibromodulin, survivin, oncofetal antigen-immature laminin receptor protein (OFA-iLRP), B-melanoma antigen (BAGE), the carboanhydrase 9 (CA9/G250), melanoma antigen (MAGE1), the preferentially expressed antigen in melanoma (PRAME), proteinase, Syntaxin, human telomerase catalytic subunit (hTERT) and the Wilms tumor gene 1 (WT1), the renal cell cancer antigen NY-Ren60, as well as six LAAs defined previously by serological analysis of recombinant cDNA expression libraries of myeloid leukemias patients: the receptor for hyaluronic acid mediated motility (RHAMM/CD168), the M-phase phosphoprotein 11 (MPP11), the particularly interesting new Cys-His protein (PINCH), the heat shock protein (HSJ2), the myc-associated zinc-finger protein (MAZ). Peripheral blood mononuclear cells from 30 B-CLL patients and 20 healthy volunteers (HVs) were evaluated by conventional and quantitative RT-PCR. mRNA of RHAMM, fibromodulin, syntaxin and NY-Ren60 was expressed in 55 - 90 % and of HSJ2, MAZ and OFA-iLRP in 90 - 100 % of the patients. Only RHAMM, fibromodulin, PRAME and MPP11 showed expression in B-CLL patients, but not in HVs. RHAMM mRNA expression was significantly higher in B-CLL patients than in HVs. Specific cytotoxic T lymphocyte responses in B-CLL patients against RHAMM/CD168 were measured in vitro. In mixed lymphocyte peptide cultures, RHAMM specific responses by CD8+HLA-A2/R3tetramer+CCR7-CD45RA high effector T-cells were detected. We conclude that RHAMM/CD168 might be an interesting target for future immunotherapies in B-CLL patients.dc.description.abstract
Languageendc.language.iso
PublisherUniversität Ulmdc.publisher
LicenseStandard (Fassung vom 03.05.2003)dc.rights
Link to license texthttps://oparu.uni-ulm.de/xmlui/license_v1dc.rights.uri
KeywordB-cell chronic lymphocytic leukemia (B-CLL)dc.subject
KeywordLeukemia associated antigens (LAAs)dc.subject
KeywordReceptor for hyaluronic acid mediated motility (RHAMM/CD168)dc.subject
KeywordTumor associated antigens (TAAs)dc.subject
Dewey Decimal GroupDDC 610 / Medicine & healthdc.subject.ddc
MeSHLeukemia, lymphocytic, chronicdc.subject.mesh
MeSHT-lymphocytes, cytotoxicdc.subject.mesh
TitlemRNA expression of tumor associated antigens in patients with chronic lymphocytic leukemiadc.title
Resource typeDissertationdc.type
DOIhttp://dx.doi.org/10.18725/OPARU-561dc.identifier.doi
URNhttp://nbn-resolving.de/urn:nbn:de:bsz:289-vts-53857dc.identifier.urn
GNDB-Zell-Leukämiedc.subject.gnd
FacultyMedizinische Fakultätuulm.affiliationGeneral
Date of activation2005-11-16T23:38:42Zuulm.freischaltungVTS
Peer reviewneinuulm.peerReview
Shelfmark print versionZ: J-H 10.907 ; W: W-H 8.856uulm.shelfmark
DCMI TypeTextuulm.typeDCMI
VTS-ID5385uulm.vtsID
CategoryPublikationenuulm.category


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record